• 1
    Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996; 55: 75660.
  • 2
    Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005; 142: 95362.
  • 3
    Petri M. Disease activity assessment in SLE: do we have the right instruments? Ann Rheum Dis 2007; 66 Suppl 3: iii614.
  • 4
    Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus: a prospective cohort study. Arthritis Rheum 1991; 34: 93744.
  • 5
    Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000; 27: 3779.
  • 6
    Brunner HI, Feldman BM, Bombardier C, Silverman ED. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1999; 42: 135460.
  • 7
    Buyon JP, Tamerius J, Belmont HM, Abramson SB. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus: comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992; 35: 102837.
  • 8
    Ho A, Magder LS, Barr SG, Petri M. Decreases in anti–double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 23429.
  • 9
    Edwards CJ, Lian TY, Badsha H, Teh CL, Arden N, Chng HH. Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome. Lupus 2003; 12: 6726.
  • 10
    D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007; 369: 58796.
  • 11
    Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus: a 5-yr prospective study. Rheumatology (Oxford) 2004; 43: 103944.
  • 12
    Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007; 22: 25319.
  • 13
    Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 1996; 156: 133744.
  • 14
    Hanly JG, McCurdy G, Fougere L, Douglas JA, Thompson K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 2004; 31: 215662.
  • 15
    Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006; 65: 117583.
  • 16
    Lacaille D, Clarke AE, Bloch DA, Danoff D, Esdaile JM. The impact of disease activity, treatment and disease severity on short-term costs of systemic lupus erythematosus. J Rheumatol 1994; 21: 44853.
  • 17
    Panopalis P, Yazdany J, Gillis JZ, Julian L, Trupin L, Hersh AO, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum 2008; 59: 178895.
  • 18
    Sutcliffe N, Clarke AE, Taylor R, Frost C, Isenberg DA. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001; 40: 3747.
  • 19
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 20
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 63040.
  • 21
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 3639.
  • 22
    Zhu TY, Tam LS, Lee VW, Hwang WW, Li TK, Lee KK, et al. Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. Rheumatology (Oxford) 2008; 47: 14225.
  • 23
    Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Joh T, and the LJP 394 Investigator Consortium. Relationship between anti–double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52: 112937.
  • 24
    Alarcon-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, et al, and the LJP 394 Investigator Consortium. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003; 48: 44254.
  • 25
    ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599608.
  • 26
    Leung GM, Bacon-Shone J. Hong Kong's health system: reflections, perspectives and visions. Hong Kong: Hong Kong University Press; 2006.
  • 27
    Grant C. The Hong Kong health care systems. Sydney: University of New South Wales; 1998.
  • 28
    Woo J, Lau E, Lau CS, Lee P, Zhang J, Kwok T, et al. Socioeconomic impact of osteoarthritis in Hong Kong: utilization of health and social services, and direct and indirect costs. Arthritis Rheum 2003; 49: 52634.
  • 29
    Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998; 13: 17.
  • 30
    Weiss JE, Sison CP, Ilowite NT, Gottlieb BS, Eberhard BA. Flares in pediatric systemic lupus erythematosus. J Rheumatol 2007; 34: 13414.
  • 31
    FitzGerald JD, Grossman JM. Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients. Lupus 1999; 8: 63844.
  • 32
    Ng KP, Manson JJ, Rahman A, Isenberg DA. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006; 55: 9004.
  • 33
    Nossent JC. Course and prognostic value of Systemic Lupus Erythematosus Disease Activity Index in black Caribbean patients. Semin Arthritis Rheum 1993; 23: 1621.
  • 34
    Ibanez D, Urowitz MB, Gladman DD. Summarizing disease features over time. I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol 2003; 30: 197782.
  • 35
    Hermosillo-Romo D, Brey RL. Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Pract Res Clin Rheumatol 2002; 16: 22944.
  • 36
    Clarke AE, Penrod J, St Pierre Y, Petri MA, Manzi S, Isenberg DA, et al, and the Tri-Nation Study Group. Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. J Rheumatol 2000; 27: 2597604.